EF-41/KEYNOTE D58: Phase 3 Trial of Optune With Temozolomide and Pembrolizumab
Phase 3
741
about 4.2 years
18+
30 sites in AZ, CA, FL +16
What this study is about
This trial is testing whether using the Optune device with maintenance Temozolomide chemotherapy agent and pembrolizumab improves survival compared to using the Optune device with maintenance Temozolomide chemotherapy agent and placebo in people who have newly diagnosed Glioblastoma. The primary goal of it is to see if it increases overall survival.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Pembrolizumab
- 2.Take Placebo
- 3.Take Temozolomide
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer), temozolomide
infusion, injection, intravenous
Primary: Overall survival
Secondary: Progression-Free Survival (PFS) per RANO 2.0 assessed by investigator
Oncology